The most significant and widely used ICI in non-small cell lung cancer (NSCLC) are those targeting the proteins programmed cell death protein-1 and programmed cell death ligand-1 (PD-1/PD-L1) 1. This evidence concerns the gene CD274 and non-small cell lung carcinoma.